Global non-alcoholic fatty liver disease & NASH market is projected to reach at a market value of US$62.06 Billion by 2031: Visiongain Research Inc Global Non-alcoholic Fatty Liver Disease & NASH Market Forecast 2021-2031: - By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity, Other Disease Causes) By...

Algernon Pharmaceuticals Announces Reduction of Key Secondary Marker of Fibrosis in Pre-Clinical NASH Study VANCOUVER, British Columbia, April 01, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...

Nash Pharmaceuticals to Present Pre-Clinical Data on Non-Alcoholic Fatty Liver Disease at 2nd Global NASH Congress in London, UK VANCOUVER, British Columbia, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (the “Company” or “Nash...